Compugen (CGEN)

• Market cap: $157M
• 1 day: 0.6%
• 5 days: -1.18%
• 1 month: -14.72%
• 3 months: 1.82%
• 6 months: 13.51%
• Year to date: 8.39%
• 1 year: -23.29%
• 5 years: -87.16%
• 10 years: -64.41%
• Sector: Healthcare
• Industry: Biotechnology

About: Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Employees: 74